Browse by category

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery is costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to research, ‘Understanding insurance-based differential healthcare costs for GLP-1ra versus bariatric surgery (abstract id: 4339)’, presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery. “As GLP-1 use bec

Bariatric surgery can save patients thousands of dollars in health care costs over the long run, according to research from Duke...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are cost effective in the long term only when combined with bariatric surgery,...

Introducing RefluxStop device (Implantica) as a treatment option for gastroesophageal reflux disease (GERD) patients treated within the...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

An economic evaluation comparing endoscopic sleeve gastroplasty (ESG) with semaglutide for treating class II obesity has suggested ESG is...

A new USC Schaeffer Center white paper finds the value to society of Medicare coverage for new classes of weight loss drugs would equal...

A study that compared expenditures for diabetes medications before and after metabolic surgery among patients with diabetes in Michigan...